Various risk factors, including sex, age, diabetes, obesity, and hypertension, are linked to an increased risk of doxorubicin-induced cardiotoxicity in cancer patients.
What are the risk factors for doxorubicin-induced cardiotoxicity in cancer patients?
Understanding risk factors for doxorubicin-induced cardiotoxicity can help tailor therapeutic approaches in cancer patients with cardiovascular risk factors.
Doxorubicin (DOX) is an anthracycline antibiotic widely used as a chemotherapeutic agent to treat solid tumours and hematologic malignancies. Although useful in the treatment of cancers, the benefit of DOX is limited due to its cardiotoxic effect that is observed in a large number of patients. In the literature, there is evidence that the presence of various factors may increase the risk of developing DOX-induced cardiotoxicity. A better understanding of the role of these different factors in DOX-induced cardiotoxicity may facilitate the choice of the therapeutic approach in cancer patients suffering from various cardiovascular risk factors. In this review, we therefore discuss the latest findings in both preclinical and clinical research suggesting a link between DOX-induced cardiotoxicity and various risk factors including sex, age, ethnicity, diabetes, dyslipidaemia, obesity, hypertension, cardiovascular disease and co-medications.
Belger et al. (Wed,) conducted a review in Doxorubicin-induced cardiotoxicity. Cardiovascular risk factors (e.g., age, sex, diabetes, hypertension) was evaluated on Doxorubicin-induced cardiotoxicity. Various risk factors, including sex, age, diabetes, obesity, and hypertension, are linked to an increased risk of doxorubicin-induced cardiotoxicity in cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: